vTv Therapeutics Inc.
VTVT
$33.28
-$0.43-1.28%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -98.30% | -98.30% | -98.30% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -98.30% | -98.30% | -98.30% | -- |
| Cost of Revenue | 54.69% | 41.37% | 12.14% | 51.98% | 28.16% |
| Gross Profit | -69.64% | -54.74% | -23.12% | -74.36% | -16.87% |
| SG&A Expenses | 9.49% | 0.74% | 3.44% | 7.63% | 14.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.21% | 19.35% | 7.47% | 1.50% | -1.20% |
| Operating Income | -35.68% | -24.26% | -12.10% | -5.71% | 5.18% |
| Income Before Tax | -37.49% | -25.52% | 5.67% | 12.29% | 12.94% |
| Income Tax Expenses | -- | -100.00% | -100.00% | -100.00% | -- |
| Earnings from Continuing Operations | -36.89% | -24.97% | 6.04% | 12.62% | 12.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -3.23% | 11.49% | -17.45% | -24.68% | -25.77% |
| Net Income | -46.11% | -28.21% | 3.08% | 9.35% | 8.83% |
| EBIT | -35.68% | -24.26% | -12.10% | -5.71% | 5.18% |
| EBITDA | -36.12% | -24.57% | -12.29% | -5.79% | 5.20% |
| EPS Basic | 1.99% | 26.61% | 54.41% | 65.51% | 64.87% |
| Normalized Basic EPS | -2.79% | 24.33% | 52.72% | 64.17% | 67.36% |
| EPS Diluted | 1.99% | 26.61% | 54.41% | 65.51% | 64.87% |
| Normalized Diluted EPS | -2.79% | 24.33% | 52.72% | 64.17% | 67.36% |
| Average Basic Shares Outstanding | 49.12% | 53.76% | 71.32% | 140.71% | 170.79% |
| Average Diluted Shares Outstanding | 49.12% | 53.76% | 71.32% | 140.71% | 170.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |